Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma
用户lNno7CpulhD4
1个月前
67
10
已完结
1. 系统已在2025-10-27 14:31:28对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/jco-24-02158
文献链接: https://ascopubs.org/doi/10.1200/JCO-24-02158
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Nirav N. Shah; Alfredo S. Colina; Bryon D. Johnson; Aniko Szabo; Fateeha Furqan; Tyce Kearl; Dina Schneider; Marlenny Vargas-Cortes; Jessica L. Schmeling; Michael B. Dwinell; Katie Palen; Walter Longo; Peiman Hematti; Anthony E. Zamora; Parameswaran Hari; Daniel Bucklan; Ashley Cunningham; Mehdi Hamadani; Timothy S. Fenske
